PTCT241220P46000
- 1.20
- 0.000.00%
PTC Therapeutics Newsroom
Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $67
PTC Therapeutics: Hold Rating Amid Strategic Collaboration With Novartis and Clinical Uncertainties
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $32
Citigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $32
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $56
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $41 to $68
UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating
PTC Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $56
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
PTC Therapeutics' Strategic Collaboration With Novartis Boosts Buy Rating
Hold Recommendation for PTC Therapeutics: Balancing Promising Prospects With Regulatory and Competitive Challenges
RBC Capital Remains a Hold on PTC Therapeutics (PTCT)
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $52
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52
TD Cowen Remains a Hold on PTC Therapeutics (PTCT)
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Announces Target Price $31
PTC Therapeutics: Sell Rating Due to Unmet Trial Goals and Overvaluation Concerns
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC Therapeutics Analyst Ratings